User profiles for Jason Zhu

Jason Zhu, MD

- Verified email at atriumhealth.org - Cited by 1294

Jason Yue Zhu

- Verified email at stanford.edu - Cited by 681

Deep learning in asset pricing

L Chen, M Pelger, J Zhu - Management Science, 2024 - pubsonline.informs.org
We use deep neural networks to estimate an asset pricing model for individual stock returns
that takes advantage of the vast amount of conditioning information, keeps a fully flexible …

A wireless and battery-less implant for multimodal closed-loop neuromodulation in small animals

…, W Bai, H Guo, T Liu, H Bai, G Monti, J Zhu… - Nature Biomedical …, 2023 - nature.com
Fully implantable wireless systems for the recording and modulation of neural circuits that
do not require physical tethers or batteries allow for studies that demand the use of …

Unlocking P (V): Reagents for chiral phosphorothioate synthesis

…, IM Mcdonald, RE Olson, Y Zhu, C Hang, J Zhu… - Science, 2018 - science.org
Phosphorothioate nucleotides have emerged as powerful pharmacological substitutes of
their native phosphodiester analogs with important translational applications in antisense …

Forest through the trees: Building cross-sections of stock returns

S Bryzgalova, M Pelger, J Zhu - Available at SSRN 3493458, 2020 - papers.ssrn.com
We build cross-sections of asset returns for a given set of characteristics, that is, managed
portfolios serving as test assets, as well as building blocks for tradable risk factors. We use …

[HTML][HTML] Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond

J Zhu, AJ Armstrong, TW Friedlander, W Kim… - … for immunotherapy of …, 2018 - Springer
Immune checkpoint inhibitors targeting the PD-1 pathway have greatly changed clinical
management of metastatic urothelial carcinoma and metastatic renal cell carcinoma. However, …

Temporal trends in the treatment of early-and advanced-stage laryngeal cancer in the United States, 1985-2007

AY Chen, S Fedewa, J Zhu - Archives of Otolaryngology–Head & …, 2011 - jamanetwork.com
Objective To describe trends and 4-year survival rate of surgical and nonsurgical treatment
for laryngeal cancer. Design Observational cross-sectional study. Patients A total of 131 694 …

Applications of targeted gene capture and next-generation sequencing technologies in studies of human deafness and other genetic disabilities

X Lin, W Tang, S Ahmad, J Lu, CC Colby, J Zhu, Q Yu - Hearing research, 2012 - Elsevier
The goal of sequencing the entire human genome for $1000 is almost in sight. However, the
total costs including DNA sequencing, data management, and analysis to yield a clear data …

[HTML][HTML] LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types

…, R Sedhom, EB Schwartz, J Zhu… - … for immunotherapy of …, 2021 - ncbi.nlm.nih.gov
Background Low-density lipoprotein receptor-related protein 1b (encoded by LRP1B) is a
putative tumor suppressor, and preliminary evidence suggests LRP1B-mutated cancers may …

3D Graphene Network with Covalently Grafted Aniline Tetramer for Ultralong‐Life Supercapacitors

…, S Aguilar, M Anderson, JZJ Zhu… - Advanced Functional …, 2021 - Wiley Online Library
The conducting polymer polyaniline (PANI) has been considered to be a promising
pseudocapacitive electrode material for supercapacitors due to its high specific capacitance, low cost…

[HTML][HTML] Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors

…, K Shirai, K Dragnev, LJ Tafe, J Zhu… - … for immunotherapy of …, 2019 - Springer
Background PD-L1 immunohistochemistry (IHC) has been traditionally used for predicting
clinical responses to immune checkpoint inhibitors (ICIs). However, there are at least 4 …